SCHEMBL25136149

SCHEMBL25136149

C=C(OCC)c1cc(C(F)(F)F)nc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.37
ALDH1A1 P00352 6/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 5/20 0.36
HSD17B10 Q99714 5/20 0.36
NPSR1 Q6W5P4 5/20 0.36
TP53 P04637 4/20 0.36
TLR9 Q9NR96 3/20 0.36
BCL2A1 Q16548 2/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HTT P42858 2/20 0.36
ALOX15 P16050 2/20 0.36
BID P55957 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
S1PR4 O95977 1/20 0.35
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397915 0.85 P2RY12 (0.31)
SCHEMBL25136323 0.82 CYP1A2 (0.45) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL26870603 0.80 KMT2A (0.38) ALDH1A1KMT2AMAPTMEN1MAPK1
SCHEMBL29882431 0.79 HSP90AA1 (0.39) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL23580481 0.79 HSP90AA1 (0.39) HPGDALDH1A1KMT2AMAPTMEN1
SCHEMBL16397702 0.79 ALDH1A1 (0.31) ALDH1A1
SCHEMBL17728111 0.78 GLP1R (0.32) ALDH1A1MAPTMAPK1HSD17B10NPSR1
SCHEMBL16398279 0.77
SCHEMBL16398280 0.77
SCHEMBL16397845 0.76 GLP1R (0.31) LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025229624-A2 NEW CD38 INHIBITORS NAPA THERAPEUTICS LIMITED (GB) 2025-11-06 WO disclosed
EP-4370512-A1 CD38 MODULATORS AND METHODS OF USE THEREOF Cytokinetics, Inc. (US) 2024-05-22 EP disclosed
CN-117813296-A CD38 modulators and methods of use thereof 赛特凯恩蒂克公司 2024-04-02 CN disclosed
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. 2023-04-20 US disclosed
WO-2023288195-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. (US) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CD38, CXCR4, FCGRT HPGD 754/4885ALDH1A1 358/4885KMT2A 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.